Skip to main content
Home
FULL MENU Close Menu
Home
Home

Mary Jo Dales

News

Checkpoint inhibitor rechallenge is possible for select patients

Author:
Mary Jo Dales
Publish date: June 6, 2019

Rechallenge resulted in the recurrence of a grade 2 or higher immune-related adverse event (irAE) in 55% of rechallenged patients, but no deaths...

  • Read More

News

FDA approves abemaciclib plus aromatase inhibitor as initial therapy

Author:
Mary Jo Dales
Publish date: February 26, 2018

Abemaciclib plus an aromatase inhibitor was approved as initial endocrine-based therapy in women with HR-positive, HER2-negative metastatic breast...

  • Read More

News

Imfinzi approved for stage III unresectable NSCLC

Author:
Mary Jo Dales
Publish date: February 17, 2018
  • Read More

News

Only half of appropriate COPD patients get long-acting bronchodilators

Author:
Mary Jo Dales
Publish date: October 25, 2017

The findings beg the issue of why clinicians overrely on short-acting rather than recommended long-acting bronchodilators for maintenance...

  • Read More

News

Lomitapide manufacturer will plead guilty to two misdemeanor charges of misbranding

Author:
Mary Jo Dales
Publish date: September 23, 2017

Lomitapide's rare disorder target was portrayed as vague to extend its use to more patients, according to the FDA.

  • Read More

News

Polycythemia vera test detects JAK2 V617F/G1849T mutation

Author:
Mary Jo Dales
Publish date: April 7, 2017

The ipsogen JAK2 RGQ PCR Kit has been given marketing authorization by the Food and Drug Administration.

  • Read More

Article

VIDEO: CPX-351 may allow more high-risk AML patients to have allogeneic transplants

Author:
Mary Jo Dales
Publish date: December 4, 2016

SAN DIEGO – Induction therapy with the investigational drug CPX-351 (Vyxeos), a liposomal formulation of cytarabine and daunorubicin, allowed more...

  • Read More

Article

Factor VIII microcapsules eyed for eluding neutralizing antibodies

Author:
Mary Jo Dales
Publish date: November 11, 2016

Using platelet microcapsules to deliver factor VIII, a process that is expected to increase factor VIII efficacy and avoid the development of...

  • Read More

Article

Investigational AML drugs boosted remission rates

Author:
Mary Jo Dales
Publish date: November 9, 2016

CPX-351 (Vyxeos), a liposomal formulation of cytarabine and daunorubicin, allowed a higher proportion of patients over age 60 with secondary AML...

  • Read More

Article

A notepad that says, "Diagnosis COPD"

Oxygen therapy no advantage in stable COPD with moderate desaturation

Author:
Mary Jo Dales
Publish date: October 26, 2016

Long-term supplemental oxygen had no benefit on multiple outcome measures in patients with stable COPD and resting or exercise-induced moderate...

  • Read More

Article

Age of blood did not affect mortality in transfused patients

Author:
Mary Jo Dales
Publish date: October 24, 2016

In-hospital mortality did not vary for patients who received transfusions of blood that had been stored for 2 weeks and for patients who got blood...

  • Read More

Article

Minimal residual disease status predicts 10-year survival in CLL

Author:
Mary Jo Dales
Publish date: October 13, 2016

Patients who have chronic lymphocytic leukemia and achieve minimal residual disease negativity have a high probability of long-term progression-...

  • Read More

Article

CD49d trumps novel recurrent mutations for predicting overall survival in CLL

Author:
Mary Jo Dales
Publish date: October 13, 2016

CD49d was a strong predictor of overall survival in a cohort of 778 unselected patients with chronic lymphocytic leukemia.

  • Read More

News

VTE risk appears to vary over time in patients with multiple myeloma

Author:
Mary Jo Dales
Publish date: August 12, 2016

Key clinical point: Patients with multiple myeloma should be assessed for VTE risk and thromboprophylaxis on an ongoing basis throughout the...

  • Read More

News

Quality of life measures comparable for panobinostat or placebo in combination with bortezomib and dexamethasone

Author:
Mary Jo Dales
Publish date: August 11, 2016

Key clinical point: Quality of-life measures were comparable for multiple myeloma patients whether they received panobinostat or placebo in...

  • Read More

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • last »

Privacy Policy

Do Not Sell My Personal Information

Terms of Use

Editorial Policy

Cookie Policy

Ad Policy

Medscape Customer Support

Frequently Asked Questions

 

Advertise with MDedge

See more with MDedge! See our Other Publications

MDedge: Keeping You Informed. Saving You Time.

Copyright  © 2021 Frontline Medical Communications Inc., Parsippany, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Close